EHA 2015 | Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia
Giuseppe Saglio • 12 Jun 2015
At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML).
